{{Infobox drug
| drug_name         =Regrelor
| INN               =
| type              =<!-- empty -->
| IUPAC_name        = [(2S,3aR,4R,6R,6aR)-6-[6-(ethylcarbamoylamino)purin-9-yl]-2-[(E)-2-phenylethenyl]-3a,4,6,6a-tetrahydrofuro[4,3-d][1,3]dioxol-4-yl]methyl dihydrogen phosphate
| image             = Regrelor in ChemDraw 16.svg
| image2            = RegrelorSpin.gif
| alt               = 
| caption           =
<!-- Clinical data -->
| pronounce         =
| tradename         = 
| Drugs.com         = 
| MedlinePlus       = 
| pregnancy_AU      = <!-- A/B1/B2/B3/C/D/X -->
| pregnancy_AU_comment = 
| pregnancy_US      = <!-- A/B/C/D/X/N -->
| pregnancy_category= 
| routes_of_administration = 
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_AU_comment =
| legal_BR =  <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C4, C5, D1, D2, E, F-->
| legal_BR_comment =
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_DE = <!-- Anlage I, II, III -->
| legal_NZ = <!-- Class A, B, C -->
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM / Class A, B, C -->
| legal_US = <!-- OTC/Rx-only/Schedule I, II, III, IV, V -->
| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV-->
| legal_status      = <!-- Free text -->
<!-- Pharmacokinetic data -->
| bioavailability   = 
| protein_bound     = 
| metabolism        = 
| metabolites       =
| onset             = 
| elimination_half-life = 
| duration_of_action =
| excretion         = 
<!-- Identifiers -->
| CAS_number        =787548-03-2
| SMILES = CCNC(=O)NC1=NC=NC2=C1N=CN2C3C4C(C(O3)COP(=O)(O)O)OC(O4)C=CC5=CC=CC=C5
| StdInChI=1S/C22H25N6O8P/c1-2-23-22(29)27-19-16-20(25-11-24-19)28(12-26-16)21-18-17(14(34-21)10-33-37(30,31)32)35-15(36-18)9-8-13-6-4-3-5-7-13/h3-9,11-12,14-15,17-18,21H,2,10H2,1H3,(H2,30,31,32)(H2,23,24,25,27,29)/b9-8+/t14-,15+,17-,18-,21-/m1/s1
| StdInChIKey = NXHAXEBZOXCDKD-XIXRRVGJSA-N
| class             = [[antiplatelet drug]]
| ATCvet            = 
| ATC_prefix        = <!-- 'none' if uncategorised -->
| ATC_suffix        = 
| PubChem           = 11273179
| UNII = Q6C8TY6SW1
| KEGG = D08983
| ChEMBL = 261244
| DrugBank          = 
| ChemSpiderID      = 9448187
<!-- Chemical and physical data -->
| chemical_formula  = C<sub>22</sub>H<sub>25</sub>N<sub>6</sub>O<sub>8</sub>P
| molecular_weight  = 532.45 g/mol
}}

'''Regrelor''' (also known as '''INS50589''') is an experimental [[antiplatelet drug]] that was under investigation by [[Merck & Co.|Merck Sharp and Dohme]] in human [[clinical trials]]. Although it was initially found to be well-tolerated in healthy subjects, safety concerns led to cessation of clinical trials. 

==Medical uses==
Regrelor is an experimental drug. It is classified as an antiplatelet medication.<ref name="Moliterno Lit Review">{{cite journal|last1=Moliterno|first1=DJ|title=Advances in antiplatelet therapy for ACS and PCI.|journal=J Interv Cardiol.|date=2008|volume=21|issue=Suppl 1|pages=S18-24|doi=10.1111/j.1540-8183.2008.00409.x|accessdate=3 August 2017}}</ref> It was under investigation for use in [[thrombosis|blood clotting]] problems,<ref name="AdisInsight">{{cite web|title=Regrelor - AdisInsight|url=http://adisinsight.springer.com/drugs/800022230|website=adisinsight.springer.com|publisher=Springer International Publishing AG|accessdate=3 August 2017}}</ref> as well as during [[coronary artery bypass surgery]].<ref name="MedChem III" />
===Available forms===
Regrelor is available in an [[intravenous]] formulation.<ref name="Moliterno Lit Review" />

==Pharmacology==
Regrelor is classified as an [[P2Y12|purinergic P2 receptor]] (P2Y<sub>12</sub>) [[Adenosine diphosphate receptor inhibitor|antagonist]].<ref name="PubChem">{{cite web|title=Regrelor|url=https://pubchem.ncbi.nlm.nih.gov/compound/Regrelor|website=pubchem.ncbi.nlm.nih.gov|publisher=National Center for Biotechnology Information|accessdate=3 August 2017}}</ref> Other compounds in the same mechanistic class include [[clopidogrel]] and [[ticagrelor]]. It is characterized as a [[Receptor antagonist#Reversibility|reversible]], [[Competitive antagonist|competitive]] receptor antagonist.<ref name="Johnson et al Phase1">{{cite journal|last1=Johnson|first1=FL|last2=Boyer|first2=JL|last3=Leese|first3=PT|last4=Crean|first4=C|last5=Krishnamoorthy|first5=R|last6=Durham|first6=T|last7=Fox|first7=AW|last8=Kellerman|first8=DJ|title=Rapid and reversible modulation of platelet function in man by a novel P2Y(12) ADP-receptor antagonist, INS50589|journal=Platelets|date=2007|volume=18|issue=5|pages=346–56|accessdate=3 August 2017}}</ref> The [[IC50]] for antagonism of ADP-induced (P2Y<sub>12</sub>-mediated) platelet aggregation was 16 nM ''in vitro''.<ref name="MedChem III" />

Regrelor's [[primary metabolite]] is called INS51088.<ref name="Johnson et al Phase1" />

==Chemistry==
Regrelor is structurally similar to [[Adenosine monophosphate|AMP]], just like [[ticagrelor]].<ref name="MedChem III" /> Regrelor has 4 [[hydrogen bond]] donors and 11 acceptors.<ref name="PubChem" /> It is produced as a di[[sodium]] salt.<ref name="pharmacodia" /> The two [[sodium]] atoms bind the negatively charged [[phosphate]] moiety in solution.<ref name="MedChem III" />
===Synthesis===
Regrelor was synthesized from [[adenosine diphosphate]] (ADP), an endogenous chemical involved in [[metabolism]].<ref name="hyperphysics.phy-astr.gsu.edu">{{cite web |author =Nave, C.R. |title=Adenosine Triphosphate |year=2005 |work=Hyper Physics [serial on the Internet] |publisher=Georgia State University |url=http://hyperphysics.phy-astr.gsu.edu/hbase/biology/atp.html}}</ref> The authors noted that the addition of a lipophilic moiety like [[cinnamaldehyde]] at the C-2' and C-3' positions, combined with ethylurea at N-6 on the [[adenine]] base, yielded regrelor.<ref name="Douglass et al Synthesis">{{cite journal|last1=Douglass|first1=JG|last2=Patel|first2=RI|last3=Yerxa|first3=BR|last4=Shaver|first4=SR|last5=Watson|first5=PS|last6=Bednarski|first6=K|last7=Plourde|first7=R|last8=Redick|first8=CC|last9=Brubaker|first9=K|last10=Jones|first10=AC|last11=Boyer|first11=JL|title=Lipophilic Modifications to Dinucleoside Polyphosphates and Nucleotides that Confer Antagonist Properties at the Platelet P2Y12 Receptor|journal=J Med Chem|date=2008|volume=51|issue=4|pages=1007–1025|doi=10.1021/jm701348d|url=http://pubs.acs.org/doi/pdf/10.1021/jm701348d|accessdate=4 August 2017}}</ref>

==History==
Regrelor was developed around the same time as [[prasugrel]] and [[cangrelor]].<ref name="Moliterno Lit Review" /> After Inspire Pharmaceuticals initially developed the drug, it was purchased by Merck Sharp and Dohme.<ref name="pharmacodia">{{cite web|title=Regrelor Disodium|url=http://en.pharmacodia.com/web/drug/1_2212.html|website=en.pharmacodia.com|publisher=Pharmacodia Holding Ltd|accessdate=3 August 2017}}</ref>

==Research==
[[Pre-clinical development|Pre-clinical experiments]] in [[Laboratory rat|rats]], dogs, and [[Animal testing on non-human primates|monkeys]] found that the drug acted quickly to inhibit platelet aggregation, and that baseline function was restored quickly after discontinuation of treatment.<ref name="Johnson et al Phase1"/>
 
In a [[phase 1 clinical trial]] sponsored by Merck Sharp and Dohme Corporation, regrelor was well-tolerated in healthy volunteers.<ref name="Phase1 clinicaltrials.gov">{{cite web|title=Study of the Tolerability, Pharmacokinetics, and Pharmacodynamics of INS50589 Intravenous Infusion in Healthy Volunteers|url=https://clinicaltrials.gov/ct2/show/NCT00099450|website=clinicaltrials.gov|accessdate=3 August 2017}}</ref><ref name="Johnson et al Phase1" /> In 2008, phase 2 trials were discontinued.<ref name="AdisInsight" /> It is believed that further development of the drug was ceased due to safety reasons.<ref name="pharmacodia" /> In the trial, there was an increased risk of [[bleeding]] for patients on regrelor.<ref name="MedChem III">{{cite web|last1=Chackalamannil|first1=S|last2=Rotella|first2=D|last3=Ward|first3=S|title=Comprehensive Medicinal Chemistry III|accessdate=3 August 2017|page=568}}</ref>

== References ==
{{Reflist|30em}}

<!--- Categories --->
[[Category:Articles created via the Article Wizard]]
[[Category:Antiplatelet drugs]]